MY103943A - Orthorhombic ciclosporin crystal form, process for its production and pharmaceutical compositions containing it - Google Patents

Orthorhombic ciclosporin crystal form, process for its production and pharmaceutical compositions containing it

Info

Publication number
MY103943A
MY103943A MYPI88001495A MYPI19881495A MY103943A MY 103943 A MY103943 A MY 103943A MY PI88001495 A MYPI88001495 A MY PI88001495A MY PI19881495 A MYPI19881495 A MY PI19881495A MY 103943 A MY103943 A MY 103943A
Authority
MY
Malaysia
Prior art keywords
ciclosporin
crystal form
production
pharmaceutical compositions
orthorhombic
Prior art date
Application number
MYPI88001495A
Inventor
Uike Yasuyuki
Danielle Giron Dr
Martin List Dr
Hans Peter Weber Dr
Friedrich Richter Dr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY103943A publication Critical patent/MY103943A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR TOPICAL FORMS, E.G. FOR DERMAL OR TOPICAL OPHTHALMIC USE, AND INJECTIBLE FORMS, E.G. FOR INTRA-LESIONAL OR INTRA-ARTICULAR INJECTION, COMPRISING CICLOSPORIN AS ACTIVE INGREDIENT IN ORTHORHOMBIC CRYSTAL FORM. CICLOSPORIN IN NON-SOLVATE ORTHORHOMBIC CRYSTAL FORM IS PREFERRED FOR USE IN THE COMPOSITIONS OF THE INVENTION, IS NEW AND ALSO PART OF THE INVENTION, TOGETHER WITH ITS USE AND PROCESSES FOR ITS PRODUCTION.
MYPI88001495A 1987-12-21 1988-12-21 Orthorhombic ciclosporin crystal form, process for its production and pharmaceutical compositions containing it MY103943A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13623087A 1987-12-21 1987-12-21
US17261388A 1988-03-24 1988-03-24
US21254888A 1988-06-28 1988-06-28

Publications (1)

Publication Number Publication Date
MY103943A true MY103943A (en) 1993-10-30

Family

ID=27384838

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI88001495A MY103943A (en) 1987-12-21 1988-12-21 Orthorhombic ciclosporin crystal form, process for its production and pharmaceutical compositions containing it

Country Status (27)

Country Link
JP (1) JPH0791316B2 (en)
KR (1) KR100188305B1 (en)
AT (1) AT403163B (en)
AU (1) AU626274B2 (en)
BE (1) BE1002665A4 (en)
CA (1) CA1341396C (en)
CH (1) CH677926A5 (en)
CY (1) CY1799A (en)
DE (1) DE3843054C2 (en)
DK (1) DK175220B1 (en)
ES (1) ES2012580A6 (en)
FI (1) FI89065C (en)
FR (1) FR2624863B1 (en)
GB (1) GB2211848B (en)
GR (1) GR1002486B (en)
HK (1) HK102894A (en)
HU (1) HU203564B (en)
IE (1) IE62006B1 (en)
IL (1) IL88719A0 (en)
IT (1) IT1235356B (en)
LU (1) LU87409A1 (en)
MY (1) MY103943A (en)
NL (1) NL195096C (en)
NO (1) NO177228C (en)
NZ (1) NZ227384A (en)
SE (1) SE503174C2 (en)
SG (1) SG99494G (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
KR0148748B1 (en) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 A multiphase cyclosporin composition
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
WO1993023010A1 (en) * 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
ES2168271T3 (en) 1992-09-25 2002-06-16 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORINS.
EP0789580B1 (en) 1994-11-03 2002-06-05 Novartis AG Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
DE19544507B4 (en) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
US6262054B1 (en) 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
ES2229473T3 (en) 1997-01-30 2005-04-16 Novartis Ag PHARMACEUTICAL COMPOSITIONS WITHOUT OIL CONTAINING CYCLOSPORINE A.
TW581681B (en) 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CN1763084B (en) * 2005-10-11 2010-04-21 山东新时代药业有限公司 High purity cyclosporin A preparation method
JP6163482B2 (en) 2011-05-27 2017-07-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Crystalline form of cyclosporin A, process for its preparation and process for its use
JP6204921B2 (en) * 2011-11-15 2017-09-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Form 2 of cyclosporin A and method for producing the same
AU2012339701B8 (en) * 2011-11-15 2017-11-16 Allergan, Inc. Autoclavable suspensions of cyclosporin A Form 2
EP3701939A1 (en) * 2011-11-15 2020-09-02 Allergan, Inc. Suspensions of cyclosporin a form 2
CA2856044C (en) 2011-11-15 2016-11-29 Allergan, Inc. Sustained action formulation of cyclosporin form 2
WO2024085235A1 (en) * 2022-10-20 2024-04-25 中外製薬株式会社 Method for producing cyclic peptide crystals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (en) * 1975-11-04 1979-12-28 Sandoz Ag
CH640519A5 (en) * 1976-04-09 1984-01-13 Sandoz Ag Process for preparing a modified form of the antibiotic S 7481/F-1
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (en) * 1977-05-10 1978-11-23 Sandoz Ag CYCLOSPORIN DERIVATIVES, THEIR USE AND MANUFACTURING
CH637124A5 (en) * 1978-10-18 1983-07-15 Sandoz Ag Antibiotic, its preparation and use

Also Published As

Publication number Publication date
AT403163B (en) 1997-11-25
GB2211848B (en) 1991-11-06
HUT49893A (en) 1989-11-28
FR2624863A1 (en) 1989-06-23
AU626274B2 (en) 1992-07-30
SG99494G (en) 1994-10-28
HU203564B (en) 1991-08-28
IT1235356B (en) 1992-06-30
ES2012580A6 (en) 1990-04-01
GB2211848A (en) 1989-07-12
LU87409A1 (en) 1989-07-07
NO177228C (en) 1995-08-09
ATA309588A (en) 1997-04-15
HK102894A (en) 1994-09-30
IL88719A0 (en) 1989-07-31
FI885869A (en) 1989-06-22
KR890009975A (en) 1989-08-05
DE3843054A1 (en) 1989-07-27
BE1002665A4 (en) 1991-04-30
SE503174C2 (en) 1996-04-15
JPH0791316B2 (en) 1995-10-04
CY1799A (en) 1995-02-17
DE3843054C2 (en) 2003-08-21
SE8804570D0 (en) 1988-12-19
FI885869A0 (en) 1988-12-19
SE8804570L (en) 1989-06-22
KR100188305B1 (en) 1999-06-01
FI89065C (en) 1993-09-30
DK705488A (en) 1989-06-22
DK175220B1 (en) 2004-07-12
NL195096C (en) 2004-02-09
FR2624863B1 (en) 1991-04-26
IE62006B1 (en) 1994-12-14
NO885625D0 (en) 1988-12-19
IT8848690A0 (en) 1988-12-20
JPH01211598A (en) 1989-08-24
NZ227384A (en) 1991-09-25
AU2705588A (en) 1989-06-22
DK705488D0 (en) 1988-12-19
NO885625L (en) 1989-06-22
GR880100850A (en) 1994-03-31
NO177228B (en) 1995-05-02
FI89065B (en) 1993-04-30
IE883779L (en) 1989-06-21
NL8803125A (en) 1989-07-17
CA1341396C (en) 2002-11-05
GB8829556D0 (en) 1989-02-08
GR1002486B (en) 1996-12-09
CH677926A5 (en) 1991-07-15

Similar Documents

Publication Publication Date Title
MY103943A (en) Orthorhombic ciclosporin crystal form, process for its production and pharmaceutical compositions containing it
IE891798L (en) Novel ó-glucosidase inhibitors
CA2000786A1 (en) 3-piperidinyl-1,2-benzisoxazoles
PH31617A (en) Novel thienylcarboxylates of amino alcohols, theirquaternary products and use of these compounds.
UA29450C2 (en) Derivatives of hydroxamic acid, a PROCESS for PREPARATION thereof, a method for influence on diseases and pharmaceutical composition containing them
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
EG18379A (en) Novel pharmacological compounds
ES479474A1 (en) Use of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3-beta-methoxy ethylester-5-isopropylester for the preparation of cerebrally active drugs.
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
GB8806892D0 (en) Lactams their synthesis & use in cosmetic compositions
DK1167354T3 (en) Racemic hypersensitivity A
HUP9602498A2 (en) Pharmaceutical compositions of antimicrobial activity
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
MY107449A (en) Bcrf1 proteins as inhibitors of interferon- gamma.
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
CA2047802A1 (en) Pharmaceutical compositions
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
IE870577L (en) Topical amide preparation
ES447307A1 (en) Novel process for the preparation of 1-N-(alpha-substituted-omega-aminoacyl)-3{40 -deoxyribostamycin
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
AU578125B2 (en) Pyrazine diazohydroxide compounds
NZ334634A (en) Use of a protein extracted from mammalian liver for treating HIV
UA26922C2 (en) Sulfamidosulfonamide derivatives having herbicidal activity and herbicidal composition based thereof
ES8204713A1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it.